D obutamine is a synthetic catecholamine with a dextro form that binds to Bl-and P2-receptors and a levo form that stimulates a-receptors.1'2 The affinity of dobutamine for cardiac muscle Bf3-and al-receptors results in a positive inotropic, and to a lesser extent, a positive chronotropic effect. These various actions are dose dependent, with increased con-tractility predominating at lower doses and progressive tachycardia developing at higher doses.
The use of dobutamine as a cardiac stress agent was first reported in 1984. 3 The rationale for this application is based on the ability of the drug to augment both heart rate and contractility, resulting in an increase in myocardial oxygen demand. Myocardial ischemia will be induced if coronary flow reserve is inadequate to meet the increase in demand.
In recent years, the use of dobutamine stress testing in ischemic heart disease has dramatically increased. [3] [4] [5] [6] [7] [8] [9] When combined with two-dimensional echocardiographic imaging, it has been shown to have expanding diagnostic and prognostic applications. Dobutamine stress testing protocols frequently use high doses of the Circulation Vol 88, No 1 July 1993 drug.7 Additionally, some investigators have supplemented the dobutamine infusion with atropine to further augment the heart rate response. 10, 11 With expanding applications and increasingly aggressive protocols, concerns about the safety of the test have arisen. To 
Arrhythmias, General Observations
Arrhythmias occurring during the dobutamine infusion are listed in Table 2 . The majority of patients had no arrhythmias (n=736, 65%) and remained in stable sinus rhythm throughout the test. The most common arrhythmia was frequent premature ventricular complexes (PVCs, six or more per minute), which occurred in 172 (15.3%) patients. Frequent premature atrial complexes (PACs, six or more per minute) developed in 7.7% of the patients. The overall incidence of arrhythmias in patients who received atropine was similar compared with those patients who were not given atropine (34% versus 35%, respectively). The overall incidence of arrhythmias was significantly higher in those patients who were evaluated under the high-dose protocol (peak dose, 50 pug/kg per minute) (24% versus 37%, P<.001, respectively). Frequent PACs (3.7% versus 7%, P<.05), supraventricular tachycardia (1.5% versus 3.1%, P<.05), and nonsustained ventricular tachycardia (0% versus 4.2%, P<.05) were more common in those evaluated under the high-dose protocol. Ventricular Tachycardia Nonsustained ventricular tachycardia (defined as more than three consecutive premature ventricular complexes) occurred in 40 patients (3.5%). Most episodes were brief, consisting of less than 10 complexes. The longest duration of ventricular tachycardia was 20 seconds. All patients were asymptomatic. In one patient, specific treatment for the arrhythmia (75 mg of intravenous lidocaine) was administered to terminate repetitive short runs of nonsustained ventricular tachycardia associated with a decrease in systolic blood pressure. Sixteen patients (40%) with nonsustained ventricular tachycardia developed evidence of myocardial ischemia during dobutamine infusion. Fourteen had stress-induced wall motion abnormalities or significant ST-segment depression. Six of these 14 patients also had angina. Two additional patients with nonsustained ventricular tachycardia experienced angina in the absence of significant echocardiographic or ECG changes.
Episodes of nonsustained ventricular tachycardia were confined to those patients evaluated with the high-dose protocol. However, the peak dose of dobutamine administered in In seven patients, transient second-degree AV block occurred, one of whom was treated with atropine. In seven patients (0.6%) with sinus rhythm at baseline, atrial fibrillation was induced during the stress test. Of these, five spontaneously reverted to sinus rhythm and two required digitalis administration to restore sinus rhythm.
Discussion
Dobutamine stress echocardiography is being increasingly used for the diagnosis of coronary artery disease in patients who cannot exercise adequately. In addition, new applications of the technique are being investigated in a broad spectrum of patients, including those with advanced coronary artery disease and recent myocardial infarction. The growing acceptance of dobutamine stress as a clinical and investigative tool underscores the need for careful documentation of the safety of this method. In many protocols, dobutamine is administered in higher doses than ordinarily would be used for therapeutic purposes,7"'1,3 potentially increasing the risk of arrhythmic and ischemic complications.
To our knowledge, this is the first large series that has examined the safety of dobutamine stress echocardiography. The study population included patients who are potentially at increased risk of complications, including those with multiple medical problems, advanced coronary artery disease, and recent myocardial infarction. The stress protocol used both aggressive dosing of dobutamine and supplemental atropine. Despite the potential for increased complications, this method of stress testing was safely performed in over 1100 subjects.
In this study, the overall frequency of side effects was higher (26%) than previously reported from our laboratory (18%) in an investigation of patients evaluated with the less aggressive (peak dose, 30 ug/kg per minute) dobutamine infusion protocol.7 However, severe side effects that warranted termination of dobutamine infusion were unusual (3%). Other investigators have also demonstrated that severe side effects are uncommon and rarely preclude completion of the test. 3, 4, 8, 9, 11, 13 Single PACs and PVCs accounted for the majority of arrhythmias that occurred during dobutamine infusion. Life-threatening arrhythmias, sustained ventricular tachycardia, and ventricular fibrillation did not occur. There have been no reports of unstable ventricular arrhythmias leading to cardiac arrest or death in 7 previous studies encompassing over 1000 patients.3'4'7-9"'1 13 In this study, the most serious arrhythmia encountered was nonsustained ventricular tachycardia, which was infrequent, and all patients were asymptomatic. Clinical predictors for the occurrence of nonsustained ventricular tachycardia were not identified. Evaluation early after myocardial infarction, abnormal rest wall motion, and atropine administration were not associated with an increased risk for the development of the arrhythmia. Ventricular tachycardia occurred only in those evaluated with the high-dose protocol, but the peak doses of dobutamine administered in subjects with and without the arrythmia were comparable.
In this study, 40% of the subjects with nonsustained ventricular tachycardia had evidence of myocardial ischemia that may have contributed to the development of this arrhythmia. Ischemia was absent in the majority of patients who had ventricular tachycardia. In these subjects, the arrhythmia may be attributed to (,1-receptor stimulation or to a dobutamine-induced reduction in plasma potassium.14"5 The frequency of ventricular ectopy and the potential for complications resulting from arrhythmias may be modified by the use of concomitant medications. Antianginal medications may limit the occurrence of ischemia and thereby reduce the frequency of ventricular arrhythmias. Atropine, by removal of parasympathetic tone, may increase the risk of serious arrhythmias in patients evaluated after myocardial infarction. The results of this study and those of McNeill et al13 suggest that the combined administration of dobutamine and atropine does not increase the occurrence of serious arrhythmias.
In this study, no patient had myocardial infarction or death resulting from provocation of myocardial ischemia. In our early experience with dobutamine stress echocardiography, the development of new wall motion abnormalities was used as an end point for termination of the test to avoid complications from extensive or prolonged ischemia. The results of this study suggest that dobutamine stress testing can be safely performed using clinical and ECG markers of ischemia as test end points. Termination of the dobutamine infusion is frequently all that is required for rapid reversal of ischemia because of the short half-life of the drug. In a proportion of patients, sublingual nitroglycerin or an intravenous (-blocker is appropriate treatment for symptomatic ischemia. In this investigation, those who had angina for 6 or more minutes were more likely to receive specific treatment compared with those without prolonged symptoms. Treatment with a (3-blocking agent is warranted in the symptomatic patient who exhibits a delay in return of the heart rate to baseline after termination of dobutamine. In addition, we use a (3-blocking agent in symptomatic patients who have extensive echocardiographic or ECG signs of ischemia. A history of angina and recent myocardial infarction identified patients who were more likely to develop angina. However, the clinical history does not allow accurate prediction of those who will develop symptomatic or extensive ischemia. For this reason, sublingual nitroglycerin and (3-blockers are available for use in every patient evaluated in our laboratory.
The results of this and previous studies using dobutamine stress indicate that this method has a comparable safety profile to pharmacological stress testing using dipyramidole. The safety of this potent coronary vasodilator was documented in a large multicenter investigation. 16 Myocardial infarction and cardiac death occurred in a few subjects, and this has been attributed to "coronary steal" from areas supplied by severely diseased vessels. Ischemic injury from reduction in coronary blood flow may be less likely to occur with dobutamine stress, which results in little or no reduction of flow through stenosed vessels. 17 
Conclusions
In this investigation, dobutamine stress echocardiography was safely performed even when an aggressive dosing protocol and supplemental atropine were used. Testing was conducted in a wide variety of patients, including those with recent myocardial infarction, without serious complications. Asymptomatic nonsustained ventricular tachycardia occurred in a small percentage of patients, but none had a life-threatening arrhythmia. Symptomatic ischemia was effectively treated by test termination, sublingual nitroglycerin, or an intravenous 3-blocker.
